CN111704642B - New flavonoid compounds Hip B and Hip C and application thereof - Google Patents
New flavonoid compounds Hip B and Hip C and application thereof Download PDFInfo
- Publication number
- CN111704642B CN111704642B CN202010605552.0A CN202010605552A CN111704642B CN 111704642 B CN111704642 B CN 111704642B CN 202010605552 A CN202010605552 A CN 202010605552A CN 111704642 B CN111704642 B CN 111704642B
- Authority
- CN
- China
- Prior art keywords
- hip
- compound
- cells
- cell
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 23
- -1 flavonoid compounds Chemical class 0.000 title claims abstract description 23
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 88
- 230000000694 effects Effects 0.000 claims abstract description 43
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 29
- 150000002632 lipids Chemical class 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 230000001413 cellular effect Effects 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 15
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 claims description 9
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 14
- 235000012054 meals Nutrition 0.000 abstract description 13
- 238000000926 separation method Methods 0.000 abstract description 8
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 6
- 239000000284 extract Substances 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 173
- 239000000243 solution Substances 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 60
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 45
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 43
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 43
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 43
- 239000005642 Oleic acid Substances 0.000 description 43
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 43
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000007788 liquid Substances 0.000 description 30
- 239000000499 gel Substances 0.000 description 28
- 241000229143 Hippophae Species 0.000 description 26
- 239000012528 membrane Substances 0.000 description 25
- 210000004413 cardiac myocyte Anatomy 0.000 description 23
- 230000003833 cell viability Effects 0.000 description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 230000002107 myocardial effect Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 17
- 238000001962 electrophoresis Methods 0.000 description 17
- 239000003292 glue Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 238000011068 loading method Methods 0.000 description 16
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 15
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 15
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 14
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 14
- 239000002033 PVDF binder Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 229910021642 ultra pure water Inorganic materials 0.000 description 14
- 239000012498 ultrapure water Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 230000006372 lipid accumulation Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 239000012224 working solution Substances 0.000 description 10
- 239000006180 TBST buffer Substances 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 238000004896 high resolution mass spectrometry Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000013498 tau Proteins Human genes 0.000 description 9
- 108010026424 tau Proteins Proteins 0.000 description 9
- 238000005138 cryopreservation Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000000946 synaptic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 238000002738 Giemsa staining Methods 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011419 induction treatment Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000008065 myocardial cell damage Effects 0.000 description 3
- 208000037891 myocardial injury Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 3
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101000746263 Conus leopardus Conotoxin Lp5.1 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002293 adipogenic effect Effects 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229930014802 neoflavonoid Natural products 0.000 description 2
- 150000002804 neoflavonoids Chemical class 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010007337 Azurin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 238000007062 Kim reaction Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 241000258239 Mantodea Species 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000012560 cell impurity Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000024346 drought recovery Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses novel flavonoid compounds Hip B and Hip C and application thereof, wherein sea buckthorn seed meal extract is eluted through an MCI gel column and then subjected to semi-preparation separation through a C18 chromatographic column, a glycol-based chromatographic column and a C18 chromatographic column in sequence, so that the novel flavonoid compounds Hip B and Hip C are obtained. The invention also provides application of the novel compounds Hip B and Hip C in preparing medicines for preventing and/or treating lipid metabolism disorder, and the activity research of the compounds Hip B and Hip C proves that the compounds Hip B and Hip C can inhibit the generation of cellular lipid and can be used for preparing medicines for preventing or treating lipid metabolism disorder diseases such as obesity, hyperlipidemia and the like.
Description
Technical Field
The invention relates to the field of flavonoid compounds and medical application thereof, in particular to novel flavonoid compounds Hip B and Hip C and application thereof.
Background
Sea buckthorn (Latin brand: hippophae rhamnoides Linn.) is a deciduous shrub of the genus Hippophae of the family Elaeagnaceae, and has the characteristics of drought tolerance and wind sand resistance, and can survive on salinized lands, so that the sea buckthorn shrub is widely used for water and soil conservation. Sea buckthorn is planted in great quantity in northwest of China and is used for desert greening.
Fructus Hippophae is nutritious, contains vitamins, flavonoids, triterpenes, oil and fatty acids, phenols, volatile oils, microelements, phospholipids, 5-hydroxytryptamine, and various amino acids and proteins required by human body.
Sea buckthorn seeds are commonly used for squeezing oil to prepare sea buckthorn oil, wherein the sea buckthorn oil contains 206 active substances beneficial to human bodies, 46 bioactive substances, and a large amount of vitamin E, vitamin A, flavone and the like. After oil extraction, a large amount of seabuckthorn seed meal is produced and is often discarded as waste or produced into dry powder to be used as feed, and the price is very low. The method has great economic significance if the utilization value of the sea buckthorn seed meal can be developed more.
In addition, the sea buckthorn contains abundant active substances which are not separated and identified, and if the new chemical components and the pharmacological actions of the new chemical components in the sea buckthorn can be subjected to deeper and finer research and active mechanism discussion, more natural plant-derived medicaments which can treat diseases are expected to be developed safely and effectively.
Disclosure of Invention
The invention provides novel flavonoid compounds Hip B and Hip C extracted from sea buckthorn seed meal and application thereof in preparing medicines for preventing and/or treating related diseases of lipid metabolism disorder, wherein the compounds have the effects of inhibiting generation and accumulation of cell lipid.
The invention provides a novel flavonoid compound in sea buckthorn, which has a structure shown in a formula I':
wherein R is 1 、R 2 、R 3 、R 4 Each independently selected from H, C1-3 alkyl groups. Further, R 1 、R 2 、R 3 、R 4 Each independently selected from H, methyl; further, the compound I' is selected from the following compounds:
the invention also provides application of the compound I' and pharmaceutically acceptable salts, hydrates or solvates thereof in preparing products for preventing and/or treating diseases related to lipid metabolism disorder.
Further, the product is a product with lipid-lowering effect, such as lipid-lowering drugs and the like.
The product or the lipid-lowering drug with the lipid-lowering effect is a product or a drug for inhibiting the generation of lipid drops in the cytoplasm of the adipocytes and reducing the content of triglyceride.
Further, the product is a product that reduces the content of cell lipid droplets and/or triglycerides.
Further, the product is a product that inhibits cellular lipid production.
Further, the product is at least one of FAS inhibitor, SREBP1 inhibitor and SCD-1 inhibitor.
Further, the product is at least one of products for preventing and/or treating obesity, hypertension, hyperlipidemia, cardiovascular diseases, metabolic syndrome related diseases.
Obesity, hypertension, hyperlipidemia, cardiovascular diseases, metabolic syndrome, etc. are all closely related to the content of plasma lipids such as Triglyceride (TG), free Cholesterol (FC), cholesterol lipid (CE) and phospholipids, and when the plasma lipids are reduced to a certain concentration range in vivo, these diseases can be effectively controlled or treated. The experiment proves that the compound IV can effectively inhibit lipid accumulation, reduce TG content, regulate the expression level of fatty acid synthesis related enzymes (such as SCD-1 and FAS) and important transcription factors (such as SREBP 1) in adipogenesis gene regulation through related signal paths, inhibit lipid production of cells, and can be used for preparing products for preventing and/or treating obesity, hypertension, hyperlipidemia, cardiovascular diseases and metabolic syndrome related diseases.
The invention also provides application of the compound I' in preparing at least one of FAS inhibitor, SREBP1 inhibitor and SCD-1 inhibitor.
The FAS inhibitor, the SREBP1 inhibitor and the SCD-1 inhibitor are medicines for reducing the protein expression level of FAS, SREBP1 and SCD-1 in cells.
The invention also provides a product comprising compound I'.
Further, the product is a medicament.
Experiments show that the compound IV, XVII, XVIII, XIX in the embodiment of the invention can effectively inhibit lipid accumulation in cells, has the effects of repairing myocardial injury, protecting myocardial cells and protecting nerves, and can be used for developing products for preventing and/or treating related diseases.
The product comprises at least compound XVIII and/or compound XIX.
On the basis of this, the invention also provides a composition comprising not only compound XVIII and/or compound XIX, but also compound IV and/or compound XVII.
Products prepared based on the combination of the above compounds are all within the scope of the present invention.
In the present invention, the percentages before the aqueous methanol solution and the aqueous ethanol solution refer to the volume fractions, for example, "40% aqueous methanol solution" refers to the volume fraction of 40% aqueous methanol solution, and the rest is the same.
The beneficial effects of the invention are as follows:
(1) According to the invention, new flavonoid compounds Hip B and Hip C are extracted from sea buckthorn seed meal, and activity research is carried out on the flavonoid compounds Hip B and Hip C, and the results show that the compound Hip B and Hip C can inhibit lipid drop accumulation, reduce TG content, regulate the expression level of important transcription factors in fatty acid synthesis related enzyme and lipogenesis gene regulation through related signal paths, inhibit cellular lipid generation, and provide a powerful direction for researching lipid metabolism disorder diseases such as obesity, cardiovascular diseases and the like.
(2) The invention more comprehensively digs the medicinal value of the sea buckthorn, expands the clinical application of the sea buckthorn, provides more reference basis for developing the medicine for treating the potential plant source of the diseases related to lipid metabolism disorder, realizes the waste utilization of sea buckthorn seed meal and changes waste into valuable.
Drawings
FIG. 1 is a chromatogram of analysis of each component of seabuckthorn seed meal;
FIG. 2 is a one-dimensional preparation diagram of a sample of SH5 component of sea buckthorn seed meal;
FIG. 3 is a two-dimensional analysis chart of each component sample in SH 5;
FIG. 4 is a purity analysis of compounds from peaks 1 to 19 in seabuckthorn seed meal;
FIG. 5 is a graphic illustration of the compound Hip B 1 H NMR spectrum;
FIG. 6 is a graphic illustration of the compound Hip B 13 C NMR spectrum;
FIG. 7 is a HSQC pattern of Compound Hip B;
FIG. 8 is a HMBC diagram of compound Hip B;
FIG. 9 is a HHCSY diagram of compound Hip B;
FIG. 10 is a NOESY diagram of Compound Hip B;
FIG. 11 is a graphic illustration of the compound Hip C 1 H NMR spectrum;
FIG. 12 is a graphic illustration of the compound Hip C 13 C NMR spectrum;
FIG. 13 is a HSQC pattern of Compound Hip C;
FIG. 14 is an HMBC diagram of compound Hip C;
FIG. 15 is a HHCSY diagram of compound Hip C;
FIG. 16 is a NOESY diagram of Compound Hip C;
FIG. 17 is the effect of Oleic Acid (OA) on HepG2 cell viability;
FIG. 18 is the effect of Oleic Acid (OA) on lipid accumulation in HepG2 cells;
FIG. 19 is the effect of Oleic Acid (OA) on FAS protein expression in HepG2 cells;
FIG. 20 is the effect of compounds Hip B, hip C on HepG2 cell viability;
FIG. 21 is the effect of compounds Hip B, hip C on lipid accumulation in HepG2 cells;
FIG. 22 is the effect of compounds Hip B, hip C on HepG2 cell adipogenic protein;
fig. 23 is a microscopic image of DoX induced H9c2 cardiomyocyte morphology (100×, n=3);
FIG. 24 is DoX pair H9c2 cardiomyocyte viabilityInfluence of forcen=3);
FIG. 25 shows the NO content of DoX to H9c2 cardiomyocyte culture supernatantn=3);
FIG. 26 shows the LDH content level of DoX on H9c2 cardiomyocyte culture supernatantn=3);
FIG. 27 shows the effect of the compounds Hip B, C on H9C2 myocardial cell viabilityn=3);
FIG. 28 shows the level of LDH induced by the compounds Hip B and C on DoX to H9C2 myocardial cell injuryn=3);
FIG. 29 shows the level of NO induced by the compounds Hip B, C on DoX to H9C2 myocardial cell injuryn=3);
FIG. 30 shows the effect of Hip B and C on DoX on H9C2 myocardial apoptosis proteinn=3);
FIG. 31 is the effect of 5. Mu.M ATRA and 40 nM OA on SH-SY5Y cell synaptic length;
FIG. 32 is the effect of compounds Hip B, hip C on SH-SY5Y cell viability;
FIG. 33 is the effect of compounds Hip B, hip C on the morphology of AD cell models;
FIG. 34 is the effect of sea buckthorn neoflavonoid on tau protein phosphorylation in SH-SY5Y cells.
Detailed Description
The preparation and application of the flavonoid compound are further described by specific examples and specific experiments, and the verification and description of the flavonoid compound on inhibiting the accumulation of cell lipid, protecting the myocardial cell injury and neuroprotection are performed.
In the embodiment of the invention, the seabuckthorn (Hippophae rhamnoides Linn.) seed meal material is supercritical CO utilized by seabuckthorn seeds produced in Shang-county of Qinghai province and Xining City 2 Seed meal after extracting seed oil.
EXAMPLE 1 preparation of novel flavonoid Compounds
1. Preparation of the Components
(1) 20.00kg of seabuckthorn (Hippophae rhamnoides Linn.) seed meal is extracted for 2 hours at 60 ℃ each time by adopting 70% ethanol solution with the feed-liquid ratio of 1:20kg/L, the extraction is carried out for 3 times, the extraction solutions of 3 times are combined and then decompressed and concentrated, and 3.50kg of seabuckthorn seed meal alcohol extract is obtained.
(2) Freeze drying the alcohol extract, crushing, sieving with 120 mesh sieve, adding small amount of methanol, mixing with 200-300 mesh normal phase silica gel in 1:1, and volatilizing until no alcohol smell. Adding 7kg of 200-300 mesh normal phase silica gel into a glass chromatographic column, eluting with dichloromethane/methanol/water=7:3:0.5 as mobile phase, eluting with 20 column volumes, and concentrating the eluent under reduced pressure to obtain extract.
(3) Dissolving the extract in 13L of 50% methanol solution, concentrating 2L under reduced pressure to 0.5L, eluting with MCI gel column, eluting with 20%, 40%, 60%, 80% and 100% methanol solution sequentially, eluting with 5 column volumes of each concentration, repeatedly sampling 2L, concentrating under reduced pressure for 3 times, and eluting to obtain 20% methanol eluate with mass of 59.12g,40% methanol eluate with mass of 71.86g,60% methanol eluate with mass of 22.35g,80% methanol eluate with mass of 20.81g, and 100% methanol eluate with mass of 35.54g.
(4) 22.35g of a 60% methanol solution elution site was dissolved in 110mL of 60% methanol solution and analyzed by HPLC under the following chromatographic conditions: chromatographic column Dubhe C18 (4.6X250 mm,5 μm), sample loading 20. Mu.L, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, gradient elution was performed using the following procedure: 0min,90% mobile phase A-10% mobile phase B;60min,80% mobile phase A-20% mobile phase B, flow rate of 1mL/min, wavelength of 254nm. The preparation method adopts a Hanbang N7010 semi-preparative liquid chromatograph to prepare a sample, and comprises the following preparation conditions: chromatographic column Dubhe C18 (20X 250mm,5 μm), sample loading 1.5mL, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, gradient elution was performed using the following procedure: 0min,90% mobile phase A-10% mobile phase B;60min,80% mobile phase A-20% mobile phase B, flow rate 19mL/min, wavelength 254nm, 6 components named SH 1-SH 6, SH1 component 0-14 min, SH2 component 14-23 min, SH3 component 23-29 min, SH4 component 29-37 min, SH5 component 37-46 min, SH6 component 46-60 min, respectively, as shown in figure 1, wherein the mass of SH5 component is 3.34g.
(5) 3.34g of SH5 component was dissolved in 8mL of dimethyl sulfoxide (DMSO) and analyzed by HPLC using Agilent1260 under the following chromatographic conditions: chromatographic column Kromasil 60-5-Diol (4.6X105 mm,5 μm), sample injection amount 0.1. Mu.L, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, gradient elution was performed using the following procedure: 0min,100% mobile phase B;60min,20% mobile phase A-80% mobile phase B, flow rate of 1mL/min, wavelength of 254nm. The preparation method adopts a Hanbang N7010 semi-preparative liquid chromatograph to prepare a sample, and comprises the following preparation conditions: kromasil 60-5-Diol (21X 250mm,5 μm), sample loading 0.4mL, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, gradient elution was performed using the following procedure: 0min,100% mobile phase B;60min,20% mobile phase A-80% mobile phase B, flow rate 21mL/min, wavelength 254nm, and retention time of 9 subfractions (SH 5-1-SH 5-9), SH 5-1-SH 5-9, respectively 0-6 min, 6-8 min, 8-22 min, 22-27 min, 27-37 min, 37-42 min, 42-55 min, 55-57 min, 57-60 min, as shown in figure 2.
2. Preparation of monomeric Compounds
(1) Separation of SH5-3 component: 0.107g of SH5-3 component was dissolved in 5mL of methanol, added with DMSO to aid dissolution, and HPLC analysis was performed using Agilent1260 under the following chromatographic conditions: chromatographic column Kromasil100-5-C18 (4.6X105 mm,5 μm) analytical column, sample size 0.1. Mu.L, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, time 60min, flow rate 1mL/min, wavelength 254nm. The preparation of the sample by using a Hanbang N7010 semi-preparative liquid chromatograph is carried out under the following conditions: chromatographic column Kromasil100-5-C18 (21X 250mm,5 μm) column was prepared with an amount of sample introduction of 0.2mL, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, flow rate 21mL/min, wavelength 254nm. The 3 peaks under SH5-3 component were obtained as peak 2, peak 3, and peak 4, and the retention time of peak 4 was 22.707min.
(2) Separation of SH5-8 components: 0.158g of SH5-8 component was dissolved in 2mL of methanol, and 400. Mu. Of LDMSO was added to aid dissolution, and HPLC analysis was performed using Agilent1260, under the following chromatographic conditions: kromasil100-5-C18 (4.6X105 mm,5 μm), sample loading 0.5. Mu.L, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, time 60min, flow rate 1mL/min, wavelength 254nm. The preparation is carried out by using a Hanbang N7010 semi-preparative liquid chromatograph under the following preparation conditions: kromasil100-5-C18 (21X 250mm,5 μm), sample loading 0.3mL, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, time 60min, flow rate 21mL/min, wavelength 254nm. 1 peak at SH5-8 was obtained as peak 17 and retention time was 26.641min.
(3) Separation of SH5-9 component: 0.153g of SH5-9 component was dissolved in 2mL of methanol, 400. Mu. Of LDMSO was added to aid dissolution, HPLC analysis was performed using Agilent1260, chromatographic conditions were: kromasil100-5-C18 (4.6X105 mm,5 μm), sample loading 0.5. Mu.L, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, time 60min, flow rate 1mL/min, wavelength 254nm. The preparation method is carried out by using a Hanbang N7010 semi-preparative liquid chromatograph, and the preparation conditions are as follows: kromasil100-5-C18 (21X 250mm,5 μm), sample loading 0.2mL, mobile phase A:0.1% formic acid in water, mobile phase B: acetonitrile, elution condition 15% B, time 60min, flow rate 21mL/min, wavelength 254nm, peak 18 and peak 19 under SH5-9, retention time 53.891min and 57.300min, respectively.
The preparative separation patterns of peaks 2, 3, 4, 17, 18, 19 are shown in FIG. 3. The compounds obtained from peaks 2, 3, 4, 17, 18, 19 were subjected to purity detection, each having a purity of greater than 92%, the purity detection chart being shown in fig. 4.
2. Structure identification of monomeric compounds
The compounds obtained by the experiment are treated by UV, HR-ESI-MS, ESI-MS, 1 H-NMR、 13 The structure analysis was carried out by the organic spectrum analysis method such as C-NMR, HMBC, HSQC, HHCOSY, TOCSY, and the results were as follows:
compound IV (peak 4): light yellow powder with a mass of 4mg, a novel compound named (6S, 9R) -9-hydro ox-4, 7-megastingmadien-3-one 9-O-beta-D-apiofuranosyl- (1- & gt 6) -beta-D-glucopyranoside (called Hyd for short), with a chemical formula of C 24 H 38 O 11 By high resolution mass spectrometry (HR-ESI-MS), its mass-to-nuclear ratio (M/Z) was 503.2414[ M+H ]] + 。 1 H NMR(600MHz,CD 3 OD):δ:5.88(1H,br,s,H-4),5.75(1H,dd,J=15.4,6.5,H-8),5.63(1H,ddd,J=15.4,9.4,0.7,H-7),4.98(1H,d,J=2.5Hz,H-1’),4.63(1H,m,H-9),4.31(1H,d,J=7.8Hz,H-1’),3.95(1H,d,J=9.7Hz,H-4’),3.93(1H,dd,J=11.3,1.8,H-6’),3.87(1H,d,J=2.5Hz,H-2’),3.74(1H,d,J=9.7Hz,H-4’),3.57(1H,dd,J=11.3,5.9,H-6’),3.56(1H,d,J=11.5Hz,H-5’),3.54(1H,d,J=11.5Hz,H-5’),3.33(1H,m,H-5’),3.32(1H,m,H-3’),3.27(1H,t,J=9.2,H-4’),3.16(1H,dd,J=9.1,7.8,H-2’),2.68(1H,d,J=9.4,H-6),2.41(1H,d,J=16.7,H-2),2.06(1H,d,J=16.7,H-2),1.96(3H,d,J=1.1Hz,H-13),1.29(3H,d,J=6.4,H-10),1.02(3H,s,H-11),0.96(3H,s,H-12); 13 C NMR(600MHz,CD 3 OD):δ:202.1(C-3),166.1(C-5),138.3(C-8),129.1(C-7),126.1(C-4),111.0(C-1’),102.6(C-1’),80.5(C-3’),78.0(C-3’,C-2’),77.2(C-9),77.0(C-5’),75.2(C-2’),75.0(C-4’),71.6(C-4’),68.6(C-6’),65.5(C-5’),56.8(C-6),48.6(C-2),37.2(C-1),28.1(C-11),27.3(C-12),24.0(C-13),21.2(C-10)。
Compound XVII (peak 17): yellow powder with a mass of 50mg, novel compound named Hippophandine A (short for Hip A) with a chemical formula of C 50 H 60 O 29 . By high resolution mass spectrometry (HR-ESI-MS), the mass-to-core ratio (M/Z) was 1123.3146[ M+H ]] + And C 50 H 61 O 29 Is consistent with calculated value 1124.3220 of (c). 1 H NMR(600MHz,CD 3 OD):δ:8.03(2H,d,J=8.8Hz,H-2′,H-6′),7.25(1H,d,J=15.9Hz,H-7″″″),6.89(2H,d,J=8.8Hz,H-3′,H-5′),6.42(2H,s,H-2″″″,H-6″″″),6.34(1H,d,J=2.0Hz,H-8),6.30(1H,d,J=2.0Hz,H-6),5.99
(1H,d,J=15.9Hz,H-8″″″),5.51(1H,br s,H-1″),5.13(1H,d,J=7.5Hz,H-1″″),4.66(1H,d,J=7.7Hz,H-1″″′),4.63(1H,d,J=7.8Hz,H-1″′),4.47(1H,dd,J=11.7,7.3Hz,H-6″″′),4.38(1H,dd,J=11.7,2.0Hz,H-6″″′),4.09(1H,br s,H-2″),4.05(1H,dd,J=9.4,3.4Hz,H-3″),3.85
(1H,dd,J=11.9,1.8Hz,H-6″′),3.74(6H,s,H-OCH 3 ),3.72(1H,t,J=9.4Hz,H-4″),3.68(1H,m,H-6″′),3.67(1H,m,H-5″″′),3.63(1H,m,H-2″″),3.62(1H,m,H-5″),3.60(1H,m,H-6″″),3.51(1H,t,J=9.1Hz,H-3″″),3.47(1H,t,J=9.1Hz,H-3″″′),3.45(1H,m,H-6″″),3.40(1H,dd,J=9.1,7.7Hz,H-2″″′),3.38(1H,t,J=9.2Hz,H-3″′),3.35(1H,t,J=9.2Hz,H-4″′),3.32(1H,t,J=9.1Hz,H-4″″),3.30(1H,m,H-4″″′),3.29(1H,m,H-5″′),3.21(1H,dd,J=9.2,7.8Hz,H-2″′),3.07(1H,m,H-5″″),1.31(3H,d,J=6.1Hz,H-6″); 13 C NMR(600MHz,CD 3 OD):δ:179.9(C-4),168.7(C-9″″″),163.2(C-7),162.6(C-5),161.7(C-4′),158.7(C-2),157.5(C-9),149.0(C-3″″″,C-5″″″),146.7(C-7″″″),139.1(C-4″″″),135.3(C-3),132.7(C-2′,C-6′),126.2
(C-1″″″),122.5(C-1′),116.3(C-3′,C-5′),115.3(C-8″″″),107.2(C-10),106.8
(C-1″″′),106.1(C-2″″″,C-6″″″),105.6(C-1″′),100.9(C-1″″),100.2(C-6),99.7(C-1″),95.3(C-8),85.5(C-2″″),82.8(C-4″),78.3(C-5″″),78.2(C-3″′),78.1(C-5″′),77.8(C-3″″′),77.6(C-3″″),76.4(C-2″″′),76.1(C-2″′),75.6(C5″″′),72.2(C-4″′),72.1(C-3″),71.6(C-4″″′),71.5(C-2″),71.1(C-4″″),69.8(C-5″),64.8(C-6″″′),62.8(C-6″′),62.3(C-6″″),56.5(C-OCH 3 ),18.3(C-6″)。
Compound XVIII (peak 18): yellow powder with mass of 41mg, new compound named Hippoph Andine B (short for Hip B) and chemical formula of C 51 H 66 O 29 . By high resolution mass spectrometry (HR-ESI-MS), the mass-to-core ratio (M/Z) was 1141.3614[ M+H ]] + And C 51 H 67 O 29 Is consistent with calculated value 1142.3690 of (c). 1 HNMR(600MHz,CD 3 OD):δ:8.09(2H,d,J=8.8Hz,H-2′,H-6′),7.02(1H,d,J=15.7Hz,H-3″″′),6.88(2H,d,J=8.8Hz,H-3′,H-5′),6.71(1H,d,J=1.6Hz,H-8),6.47(1H,d,J=1.6Hz,H-6),5.63(1H,br t,J=7.0Hz,H-5″″′),5.59(1H,br s,H-1″),5.50(1H,d,J=15.7Hz,H-2″″′),5.15(1H,d,J=7.4Hz,H-1″′),4.70(1H,d,J=7.6Hz,H-1″″),4.36(1H,d,J=7.8Hz,H-1″″″),4.33-4.39(2H,m,H-6″″),4.05(1H,br s,H-2″),3.97(1H,m,H-8″″′),3.85(2H,m,H-3″,H-6″″″),3.69(1H,m,H-6″″″),3.67(1H,m,H-2″′),3.66(1H,m,H-6″′),3.60(1H,m,H-5″),3.59(1H,m,H-5″″),3.52(1H,t,J=9.1Hz,H-3″′),3.49(1H,m,H-6″′),3.48(1H,m,H-4″),3.44(1H,t,J=9.0Hz,H-3″″),3.37(1H,m,H-2″″),3.36(1H,m,H-3″″″),3.34(3H,m,H-4″″″,H-4″″,H-4″′),3.26(1H,m,H-5″″″),3.21(1H,dd,J=9.0,7.8Hz,H-2″″″),3.11(1H,m,H-5″′),2.72(1H,m,H-9″″′),2.16-2.25(2H,m,H-6″″′),1.52-1.59(2H,m,H-7″″′),1.51(3H,br s,H-12″″′),1.25(3H,d,J=6.1Hz,H-6″),1.12(3H,d,J=6.1Hz,H-11″″′); 13 C NMR(600MHz,CD 3 OD):δ:180.1(C-4),169.0(C-1″″′),163.4(C-7),163.0(C-5),161.8(C-4′),159.1(C-2),158.0(C-9),151.2(C-3″″′),143.8(C-5″″′),135.4(C-3),134.0(C-4″″′),132.8(C-2′,C-6′),122.3(C-1′),116.4(C-3′,C-5′),115.5(C-2″″′),107.5(C-10),106.2(C-1″″),103.6(C-1″″″),101.0(C-1″′),100.6(C-6),99.7(C-1″),95.6(C-8),84.8(C-2″′),81.3(C-8″″′),78.3(C-5″′),78.0(C-3″″″),77.9(C-5″″″),77.8(C-3″″),77.7(C-3″′),76.2(C-2″″),75.7(C-5″″),75.3(C-2″″″),73.6(C-4″),72.0(C-3″),71.8(C-4″″″),71.7(C-2″,C-4″″),71.3(C-5″),70.9(C-4″′),64.6(C-6″″),62.9(C-6″″″),62.4(C-6″′),45.3(C-9″″′),31.7(C-7″″′),25.6(C-6″″′),18.2(C-6″),12.8(C-11″″′),12.1(C-12″″′)。
Compound XIX (peak 19): brown yellow powder with mass of 15mg, new compound named Hippophandine C (short for Hip C) and chemical formula of C 51 H 66 O 29 . By high resolution mass spectrometry (HR-ESI-MS), the mass-to-core ratio (M/Z) was 1141.3614[ M+H ]] + And C 51 H 67 O 29 Is consistent with calculated value 1142.3690 of (c). 1 H NMR(600MHz,CD 3 OD):δ:8.06(2H,d,J=8.8Hz,H-2′,H-6′),6.96(1H,br d,J=11.5Hz,H-3″″′),6.87(2H,d,J=8.8Hz,H-3′,H-5′),6.74(1H,d,J=1.8Hz,H-8),6.47(1H,d,J=1.8Hz,H-6),6.10(1H,dd,J=14.8,11.5Hz,H-4″″′),5.80(1H,dt,J=14.8,7.1Hz,H-5″″′),5.59(1H,br s,H-1″),5.21(1H,d,J=7.5Hz,H-1″′),4.73(1H,d,J=7.7Hz,H-1″″),4.38(1H,dd,J=12.0,2.1Hz,H-6″″),4.36(1H,d,J=7.8Hz,H-1″″″),4.34(1H,dd,J=12.0,5.6Hz,H-6″″),4.06(1H,m,H-8″″′),4.05(1H,br s,H-2″),3.85(1H,m,H-3″),3.84(1H,m,H-6″″″),3.70(2H,m,H-6″″″,H-2″′),3.66(1H,dd,J=12.1,1.7Hz,H-6″′),3.60(2H,m,H-5″,H-5″″),3.54(1H,t,J=9.1Hz,H-3″′),3.50(1H,m,H-6″′),3.48(1H,t,J=9.3Hz,H-4″),3.45(1H,t,J=9.0Hz,H-3″″),3.38(1H,m,H-2″″),3.36(3H,m,H-4″″,H-3″″″,H-4″″″),3.35(1H,m,H-4″′),3.25(1H,m,H-5″″″),3.19(1H,dd,J=9.0,7.8Hz,H-2″″″),3.12(1H,m,H-5″′),2.53(1H,dd,J=15.4,6.8Hz,H-9″″′),2.46(1H,dd,J=15.4,4.1Hz,H-9″″′),,2.36(1H,m,H-6″″′),1.79(1H,m,H-7″″′),1.78(1H,m,H-6″″′),1.62(3H,br s,H-12″″′),1.25(3H,d,J=6.1Hz,H-6″),0.82(3H,d,J=6.1Hz,H-11″″′); 13 C NMR(600MHz,CD 3 OD):δ:180.0(C-4),176.7(C-10″″′),169.9(C-1″″′),163.4(C-7),162.9(C-5),161.7(C-4′),159.1(C-2),158.0(C-9),143.8(C-5″″′),140.4(C-3″″′),135.4(C-3),132.6(C-2′,C-6′),127.9(C-4″″′),125.4(C-2″″′),122.4(C-1′),116.4(C-3′,C-5′),107.5(C-10),105.8(C-1″″),103.8(C-1″″″),100.9(C-1″′),100.6(C-6),99.8(C-1″),95.7(C-8),84.1(C-2″′),80.7(C-8″″′),78.3(C-5″′),78.1(C-3″″″),77.8(C-5″″″,C-3″″),77.7(C-3″′),76.1(C-2″″),75.7(C-5″″),75.3(C-2″″″),73.6(C-4″),72.1(C-3″),71.7(C-2″,C-4″″″),71.6(C-4″″),71.3(C-5″),71.1(C-4″′),64.9(C-6″″),62.9(C-6″″″),62.4(C-6″′),38.3(C-7″″′),38.1(C-9″″′),37.0(C-6″″′),18.1(C-6″),12.5(C-12″″′)。
The following test examples prove the beneficial effects of the novel compounds Hip B and Hip C:
test example 1 Compounds Hip B and Hip C inhibit lipid accumulation in HepG2 cells
1. Experimental method
1.1HepG2 cell culture technique
(1) In vitro culture of HepG2 cells
HepG2 cells were cultured in DMEM high-sugar medium containing 10% FBS and 1% Streptomyces lividans at 37℃and 5% CO 2 Culturing in a saturated humidity incubator.
(2) Passage of HepG2 cells
HepG2 cells were incubated at 37℃with 5% CO 2 Culturing in an incubator with saturated humidity, and when the cell fusion degree reaches more than 80%, carrying out 1:5 ratio passage on the cells.
(3) Counting of HepG2 cells
The usual tool for cell counting is a blood cell counting plate, each counting plate of the blood cell counting plate is formed by 2H-shaped grooves to form a counting pool with the height of 0.10mm, 9 large squares are arranged in the counting plate, and the cell counting area is 4 large squares at four corners. And (3) adjusting the cell count density according to the experimental requirement, recording the total number of cells of 4 large squares, and finally calculating the cell number according to a formula 1.1:
Cell number = total number of cells in 4 cells 4 x 10 4 X dilution factor
After the cell number is determined, the cell density is then adjusted according to the experimental requirements.
(4) Cryopreservation of HepG2 cells
Selecting cells in logarithmic growth phase, rapidly digesting the cells, adding the cell cryopreservation solution prepared in advance, subpackaging into sterile cell cryopreservation tubes at proper cell density, and simultaneously making time marks on tube walls so as to be capable of inquiring at any time, placing at 4 ℃ for 10min, -20 ℃ for 1h, -80 ℃ for overnight, and storing in a liquid nitrogen tank.
(5) Resuscitating HepG2 cells
And rapidly taking out the frozen cell strain from the liquid nitrogen tank, rapidly placing the frozen cell strain in a water bath at 37 ℃ for melting, rapidly culturing the cell transfer culture solution after the cells are completely fused, and replacing the fresh culture solution after the cells are attached to the wall (generally for 6 h).
1.2 Effect of varying concentrations of Oleic Acid (OA) on HepG2 cell viability
The influence of oleic acid on the cell viability of HepG2 cells is determined by adopting an SRB method, and the specific steps are as follows: (1) HepG2 cells at 5×10 4 When the cells were grown to about 70-80% in a high-sugar DMEM medium containing 10% FBS, the OA concentrations were set to 0, 0.1, 0.25, 0.5, 0.75, 1 and 2mM, respectively, and the cells were treated for 24 hours and 48 hours, respectively. (2) After the treatment of the drug, the stock solution was discarded, 100. Mu.L of fresh DMEM was added to each well, and then 25. Mu.L of 50% TCA (light-shielding, available in a gun) was added thereto, and the mixture was left at room temperature for 5min at 4℃for 1h; (3) The stock solution was discarded, each well was rinsed 5 times with flowing ddH2O, and forced out after each rinsing pass. Inverted on an ultra-clean workbench for 15min for drying (high wind); (4) 70 μl of 0.4% SRB was added to each well and shaken for 30min (protected from light). (5) The SRB dye liquor is discarded, 1% glacial acetic acid is added into each hole to be washed for 4 times, and the solution is thrown out forcefully after each washing. Inverted on an ultra-clean workbench for 15min for drying (high wind); (6) mu.L of 100mM Tribase was added to each well and the mixture was incubated with shaking at 37℃for 20min. (7) detecting the OD value at 540nm wavelength by using an enzyme-labeled instrument. Cell viability was calculated according to the formula.
Cell viability (%) = (drug group OD/blank group OD) ×100%
1.3 Effect of different time OA treatments on HepG2 cell oil Red O staining
Determination of lipid droplet size and content in cells after 0.5mM OA treatment of HepG2 cells for 0h, 24h and 48h after incubation with 0.5mM OA and test compound for 48hThe size and content of lipid droplets in cells was determined by placing sterile coverslips in 24-well plates, adding 1mL DMEM, and placing in an incubator for a 30min incubation. The medium was aspirated and the cells were incubated at 5X 10 4 Inoculating 1mL of cell suspension to a slide, adding 1mL of cell suspension to each hole, pressing the slide by a needle head, removing bubbles below the slide, culturing in an incubator, performing OA induction treatment when the cell density reaches about 90% -95%, fixing after the treatment is finished, adding an oil red O working solution prepared in advance to dye the surface of the cells, and standing in a dark place for 60min. The cells were washed with 70% ethanol, excess dye was removed, washed 3-4 times with double distilled water, observed under a microscope and photographed.
1.4 Effect of OA treatments at various times on triglyceride content in HepG2 cells
Measurement of Triglycerides in cells after 0.5mM OA treatment of HepG2 cells for 0h, 24h and 48h and measurement of Triglycerides in cells after 0.5mM OA co-incubation with test Compound for 48h, which is specifically operated by subjecting HepG2 cells to 5X 10 4 The density of each hole is inoculated into a 24-hole plate, OA induction treatment is carried out after the cell density reaches about 70% -80%, and the TG content is measured after the treatment time is over, wherein the specific method is as follows: (1) cell treatment: after the induction treatment is finished, the cell culture solution is sucked away, and after the cell culture solution is washed twice by cold PBS, the cell lysate PIPA is added for 5min to lyse (the operation is carried out on ice); (2) cell collection: after cell lysis, scraping and transferring cells from the bottom of the pore plate to a 1.5ml centrifuge tube by using a cell scraper, and directly measuring the prepared homogenate without centrifugation; (3) Adding 2 mu L of sample to be detected into each well of a 96-well plate, adding 2 mu L of distilled water into a blank well, adding 2 mu L of standard substance into a standard well, adding 160 mu L of reagent R1 into each well, uniformly mixing, incubating at 37 ℃ for 5min, and measuring the A1 value by using an enzyme-labeled instrument under the condition of 546nm wavelength; immediately thereafter, 40. Mu.L of reagent R2 was added to each sample, mixed well, and incubated at 37℃for 5min, after which the second spot absorbance A2 was read. Absorbance change of each tube △ a=a2-A1. And finally, measuring the protein concentration in the sample to be tested by means of a BCA method, and correcting.
TG content= (OD Sample of -OD Blank space )/(OD Proof mass -OD Blank space ) X calibrator concentration (mM)/protein concentration of sample to be measured (gprot/L)
1.5 Effect of various time OA treatments on Fatty Acid Synthase (FAS) protein expression in HepG2 cells
HepG2 cells were grown at 5X 10 4 Inoculating each hole into a 6-hole plate, performing OA induced differentiation when cells are completely grown to about 80% -90%, extracting cytoplasmic proteins after the induction time point is over, and performing protein electrophoresis, wherein the specific method is as follows:
(1) Extraction of total cell proteins:
after 0.5mM OA treatment of HepG2 cells for 0h, 24h and 48h and 0.5mM OA co-incubation with test compounds for 48h, the cells were collected and total proteins were extracted, and the total proteins were finally stored at-80 ℃.
(2) Protein content determination by BCA method
Taking out the frozen protein sample, diluting the protein standard with PBS buffer solution to 0.5mg/mL according to the requirements of the BCA protein quantification kit instruction, and mixing the reagent A in a ratio of 50:1: and (3) uniformly mixing the reagent B to prepare a working solution. Standards and PBS were added to 96-well plates as shown in table 3.3, with 20 μl per well, typically 3 multiplex wells per concentration, to draw standard curves. 1 μl of protein sample was added to a 96-well plate and 20 μl of PBS was added. Adding 200 mu LBCA working solution into each hole, fully and uniformly mixing, oscillating and incubating the samples at 37 ℃ for 30min by a microplate incubation oscillator, measuring the luminosity value at 562nm by an enzyme-labeling instrument, and calculating the protein concentration of the samples according to a standard curve. After the protein concentration was measured, 30. Mu.g of the protein sample was calculated, SDS-PAGE loading buffer was added, and the mixture was thoroughly mixed, and boiled in boiling water for 10 minutes to completely denature the protein. And before protein loading, the sample is centrifugally and uniformly mixed for use.
TABLE 1BCA method protein quantification Table
(1) SDS-PAGE electrophoresis: the specific operation method of protein electrophoresis is the same as the conventional method in the prior art, and according to the molecular weight of target protein, proper concentration of separating gel is selected according to table 3, according to the gel preparation description table 2, a proper solution system is prepared, finally 5% of concentrated gel on the upper layer is prepared according to table 4, after gel preparation, electrophoresis is performed as soon as possible, and electrophoresis conditions are: s1, 80V for 30min; and S2, 120V, about 2h, and ending electrophoresis when bromophenol blue in the buffer solution runs to the lowest end of the separation gel.
TABLE 2 optimal separation ranges for SDS-PAGE separating gels of different concentrations
TABLE 3 preparation of the volumes of the components required for different volumes of 10% SDS-PAGE separating gel
TABLE 4 preparation of the various Components required for different volumes of 5% SDS-PAGE concentrate gel
(2) Transferring: and (3) immediately performing transfer membrane after the protein electrophoresis is finished, wherein the specific experimental operation method is the same as the conventional method in the prior art.
(3) Closing: after the transfer, the PVDF membrane was gently removed from the transfer plate with tweezers, rinsed in TBST buffer for 5min, and immediately blocked with a TBST room temperature shaker containing 5% nonfat milk powder for 1 h.
(4) Incubation resistance: after the end of the blocking, the PVDF membrane was placed in the diluted primary antibody solution and incubated overnight at 4℃on a horizontal shaking table with slow shaking.
(5) Secondary antibody incubation: after the incubation of the primary antibody was completed and the membrane washing was completed, the PVDF membrane was placed in a solution containing HRP-labeled murine secondary antibody or rabbit secondary antibody and incubated for 1h at room temperature in a shaker.
(6) Developing: after the incubation of all antibodies is finished, the ECL method is adopted for detection, developing solution is prepared according to the proportion of 1:1, the mixed ECL is added on a PVDF film for luminescence, and a gel imaging system is used for photographing.
2. Experimental results
2.1 Effect of OA on HepG2 cell viability
The effect of Oleic Acid (OA) on the cell viability of HepG2 cells was determined using SRB, with OA concentrations of 0, 0.1, 0.25, 0.5, 0.75, 1 and 2mM, and cells treated for 24h and 48h, respectively, as shown in figure 17. The optimal treatment concentration for OA was finally determined to be 0.5mM.
2.2 Effect of OA treatment at various times on lipid accumulation in HepG2 cells
After 0.5mM OA treatment of HepG2 cells for 0h, 24h and 48h, the lipid drop content and the triglyceride content in the cells were measured, and as a result, see FIG. 18, it was found that the lipid drop and triglyceride content in the cells were significantly increased with the increase of the treatment time, and the final treatment time of OA was determined to be 48h.
2.3 Effect of OA on FAS protein expression in cells at various times
The expression level of Fatty Acid Synthase (FAS) protein in the cells was detected by Western blot after 0.5mM OA treatment of HepG2 cells for 0h, 24h and 48h, and the result (fig. 19) shows that the lipid accumulation level was highest after 0.5mM OA treatment of cells for 48h, which is consistent with the results of oil red O staining and TG content measurement, and thus the OA treatment time was 48h in the subsequent treatment.
2.4 Effect of Hip B and Hip C on HepG2 cell viability
The test adopts an SRB method to detect the influence of the compounds Hip B and Hip C on the activity of HepG2 cells. As a result of setting 6 treatment concentrations (0, 0.1, 1, 10, 50 and 100. Mu.M) for each compound, as shown in FIG. 20, cell viability was high at a compound concentration of 1. Mu.M, and when the compound concentration was 50. Mu.M or more, cell viability was affected and gradually decreased with increasing treatment concentration, so that 10. Mu.M was selected as the optimal action concentration of the compound in the subsequent experiments.
2.5 Effect of Compounds Hip B and Hip C on lipid accumulation in HepG2 cells
The effect of the compounds Hip B and Hip C on lipid accumulation in HepG2 cells was examined by oil red O staining and measurement of triglyceride content, and the results are shown in fig. 21. Compared with the normal control group, there was a large accumulation of lipid droplets and a significant increase in triglyceride content in the OA group after oleic acid treatment, whereas the lipid droplets and triglyceride content were reduced to different extents after treatment with both compounds Hip B and Hip C.
2.6 Effect of Compounds Hip B and Hip C on HepG2 cell adipogenic proteins
SCD-1 and FAS are important enzymes in de novo fatty acid synthesis. SREBP1 is an important transcription factor in the regulation of adipogenesis genes, involved in fatty acid chain synthesis by activating FAS expression. The effect of the novel flavonoids on HepG2 cell lipoproteins is shown in FIG. 22, and the protein expression levels of FAS, SREBP1 and SCD-1 are remarkably increased after oleic acid treatment compared with the normal control group, while the protein expression levels of FAS, SREBP1 and SCD-1 are reduced to different degrees after the novel flavonoids are treated.
Test example 2 protective Effect of Compounds Hip B and Hip C on doxorubicin-induced myocardial cell injury
1 experiment materials, reagents and instruments
1.1H9c2 rat cardiomyocytes
H9c2 (2-1) rat cardiomyocytes were purchased from Shanghai cell bank, national academy of sciences. H9c2 cardiomyocytes were initially subcloned from b.kimes and b.brandt by selective subculture using ventricular cells derived from BD1X rat embryonic heart tissue as the cell culture source. It exhibits specific cardiomyocyte lines with skeletal muscle and myocardial function at the same time.
1.2 materials and reagents
(1) DoX mother liquor preparation: 10mgDoX is dissolved in 3.680mL PBS to prepare mother solution with a final concentration of 5mmol/L, and the mother solution is preserved at-20 ℃ and can be diluted to 100 mu mol/L for split charging, thus avoiding repeated freezing and thawing. Note that DoX is preferably a glass vessel during the formulation process, if EP tubing concentrations are not less than 1mmol/L.
(2) Preparation of mother liquor of 5mg/mL
MTT is sensitive to bacteria and is easy to denature in light, and is required to be sterile and light-proof during preparation. Fully dissolving 0.5g MTT powder in 100mLPBS until the final concentration of MTT solution is 5mg/mL, filtering and sterilizing with 0.22 mu M microporous filter membrane, packaging into 1.5mLEP tube, and storing at-20deg.C for a long time in dark place to avoid repeated freeze thawing. Note that: when the MTT solution turns a grey green color, it is not usable.
(3) Preparation of reagent for Western blot
1) BCA working solution preparation: the required volume is prepared according to the ratio of the reagent A to the reagent B of 50:1.
2) Protein standard solution preparation: the concentration of the protein standard solution is 50mg/mL, the protein standard solution is diluted by PBS to a final concentration of 0.5mg/mL,200 mu L of the protein standard solution is split charging, and the protein standard solution is preserved at-20 ℃ and is taken at present.
3) 10% (W/V) Ammonium Persulfate (AP) solution: and (3) dissolving 0.5g of ammonium persulfate in 5.0mL of ultrapure water, subpackaging after dissolving, and preserving at-20 ℃ in a dark place for taking at present.
4) Preparing 5 XSDS-PAGE electrophoresis liquid: after Tris 15.1g,Glycine 94.0g is weighed and added with ultrapure water for ultrasonic dissolution, 5.0g of SDS is added at last to prevent foaming, and the volume is fixed to 1000mL, so that the solution can be stored at normal temperature. When the solution is used, 100mL of 5 Xelectrophoretic solution is measured, ultrapure water is added to fix the volume to 500mL, and the solution is diluted to 1 Xelectrophoretic solution.
5) Preparing 10 x membrane transferring liquid: tris 30.3g,Glycine 144.0g is weighed, and after being dissolved by ultrapure water, the volume is fixed to 1000mL. Preparing a 1X membrane transferring liquid: 50mL of 10 Xtransfer solution (1 part) was taken, 100mL of methanol (2 parts) and ultrapure water (7 parts) was added thereto to make up to 500mL, thereby obtaining 1 Xtransfer solution. Can be repeatedly used for 3-5 times and stored in a refrigerator at the temperature of 4 ℃.
6) 10×tbs solution preparation: adding ultrapure water to dissolve 12.12g of Tris and 40.03g of NaCl which are weighed, adjusting the pH to 7.6, adding ultrapure water to 500mL, and preserving in a refrigerator at 4 ℃ for later use.
7) 1 XTBST buffer preparation: the pipette sucks 500 mu L of Tween 20, adds the Tween 20 into 50mL of 10 XTBS, mixes the Tween 20 with the 50mL of 10 XTBS, adds ultrapure water to fix the volume to 500mL, mixes the Tween 20 with the 500mL of ultrapure water, and stores the Tween 20 in a refrigerator at 4 ℃ for standby. Note that: tween 20 is sticky and needs to cut off the gun head of the pipetting gun, so that the pipetting gun is convenient to suck, and the whole gun head is pumped into buffer solution.
8) Preparing a sealing liquid: weighing 0.5g of skimmed milk powder (or BSA), adding 10mL of TBST solution, mixing, and preferably mixing at a desired amount according to the proportion, and storing in refrigerator at 4deg.C. Note that only the supernatant is used in the using process, and the lower-layer particles are not used together, so that incomplete sealing is prevented, and black spots can appear on the membrane.
9) Preparing an anti-solution: antibodies such as beta-actin, COX-2, caspase-3, etc. were diluted 1:1000 with antibody dilutions. The refrigerator is stored at 4 ℃ when in use and at-20 ℃ when not in use. To extend the life of the antibody, an appropriate amount of sodium azide (NaN 3 )。
10 Preparation of secondary antibody solution: according to goat anti-rabbit or goat anti-mouse antibody: antibody dilutions = 1:2000. The antibody is stored in a refrigerator at 4 ℃ when being used, and is stored in a refrigerator at-20 ℃ when not being used.
1.3H9c2 cardiomyocyte in vitro culture
DMEM high sugar culture with 10% FBS and 1% diabody was used at 37℃on 5% CO 2 H9c2 myocardial cells are cultured in an incubator with saturated humidity, liquid is changed every other day, and subculture is carried out when the cell growth density reaches 70% -80%.
1.4H9c2 cardiomyocyte cryopreservation
H9c2 myocardial cells with the growth density reaching 70-80% and in the logarithmic growth phase are selected, and the digestion operation of the cells is carried out in the step of passage. Finally, the collected cell suspension is placed into a sterile centrifuge tube, the temperature is 25 ℃ at 1000rpm, the centrifugation is carried out for 6min, the supernatant is discarded, the trypsin effect is thoroughly removed, and the influence of cell impurity particles is removed. After resuspension of the cells with DMEM high sugar medium, the cells were counted and adjusted to the corresponding concentration. Preparing proper cell freezing solution according to the proportion of DMEM high-sugar culture medium to FBS, DMSO=5:4:1, adding the resuspended cells, lightly blowing the mixture to be uniform, and sub-packaging the mixture into sterile cell freezing tubes with proper volume, wherein each tube is 1.0-1.2 mL. After the sealing film of the freezing tube is sealed, the information of cell name, algebra, freezing date, freezing person and the like is marked, and the freezing tube is placed in an isopropanol gradient cooling box and stored for 24 hours at the temperature of minus 80 ℃ and then transferred into a liquid nitrogen tank for storage.
1.5H9c2 myocardial cell resuscitation
Preparation: before operation, the ultraviolet lamp is turned on, the ultra-clean bench is irradiated for about 30min, and after the bench is wiped by spraying with the new Jieling, the DMEM high-sugar culture medium is incubated. The water bath kettle is opened in advance to adjust the temperature to 37 ℃ in advance, then H9c2 myocardial cells taken out of the liquid nitrogen tank are rapidly put into a water bath with the temperature of 37 ℃, and shake back and forth during the period to accelerate dissolution, so that rapid dissolution within 1min is achieved. The cells in the cryopreservation tube were aspirated into DMEM high sugar medium containing 10% fbs, taking care to ensure uniform cell distribution. Labeling information such as cell name, algebra and date on culture dish, placing at 7deg.C, 5% CO 2 Culturing in a saturated humidity incubator for about 6 hours, observing cells under a microscope until the cells are completely adhered, sucking and removing the culture medium, rinsing with PBS for 2-3 times, removing residual DMSO, and replacing a new culture medium. When the cell density reaches 70% -80%, the passage operation can be performed.
1.6H9c2 cardiomyocyte passage
Culturing H9c2 myocardial cells, and carrying out subculture when the myocardial cells are fused to about 70-80%. Before operation, the ultraviolet lamp is turned on, the ultra-clean workbench is irradiated for about 30min, and the workbench surface is sprayed and wiped by the novel Jiertangling. The old medium in the dish was discarded by the pipette and washed 2 times with PBS phosphate buffer incubated at 37 ℃. A100 mm dish was added with 750. Mu.L of trypsin digestion solution containing 0.25% EDTA and the mixture was placed in an incubator for digestion for 1 to 2 minutes. Observing under a microscope, slightly shaking the wall of the culture dish when most cell gaps become large and cells almost become light-transmitting circles, and slightly falling off small amount of cells in a fine sand shape to finish digestion. The pancreatin is removed by vacuum pumping, a proper amount of culture medium is added into a liquid-transfering gun to stop digestion, and the mixture is gently blown until all the cells fall off, so that uniform cell suspension is prepared. Inoculating to a new culture dish according to the ratio of 1:2-1:4, supplementing corresponding serum and culture medium, and placing into an incubator for continuous culture.
1.7MTT method for detecting cell viability
H9c2 myocardial cells with the growth density reaching 70-80% and in the logarithmic growth phase are selected, and the digestion operation of the cells is carried out in the step of passage. Homogeneous single cell suspension was prepared with DMEM high sugar medium containing 10% fbs and inoculated at a density of 7500 cells/well into 96 Kong XiIn the cell culture plate, 200. Mu.L per well volume. At 37℃with 5% CO 2 Culturing under saturated humidity for complete cell adhesion, adding DoX with different concentrations, inducing for 24 hr, adding 20 μl of 5mg/mL MTT solution per well, incubating in incubator for 3 hr, and discarding culture medium to stop culturing. 100 mu LDMSO is added into each hole, oscillation is carried out for 10min, formazan is fully dissolved, and a multifunctional enzyme-labeled instrument is used for measuring the absorbance at 490 nm.
Cell viability (%) = (drug treated/blank OD) ×100%
1.8Griess method for detecting NO content of cell supernatant
(1) Preparing a standard substance: 1mol/L NaNO 2 Standard solution, cell culture solution (DMEM
+10% fbs) was diluted in a gradient to a series of 0,1,2,5, 10, 20, 40, 60, 100 μmol/L standard solutions for standard curve plotting.
(2) Samples were added to 96-well plates at 50 μl/well. Then, 50. Mu.L/well was added to each well, and Griess Reagent I was added at room temperature. Then, 50. Mu.L/well of each well was filled with room temperature Griess Reagent II. Finally, absorbance was measured at 540 nm.
1.9 detection of Lactate Dehydrogenase (LDH) from cell supernatants by microplate method
The specific operation method is shown in the specification.
1.10Westernblot experiment method
(1) Extraction of cellular proteins
a. Preparation: an ice-crushing bath was prepared, an EP tube was labeled, pre-chilled PBS was used, and lysates (RIPA lysis buffer: pmsf=100:1) were prepared. The vacuum pump sucks the culture medium as much as possible, and the residue of the culture medium can influence the measurement of protein absorbance, thereby influencing the accuracy of protein concentration measurement.
b. Cleaning: the round was slowly turned and cold PBS was added to prevent wash-off and suck away cells. After rinsing for 2 times, PBS is sucked away as much as possible, otherwise the concentration of protein is diluted, so that the concentration is too low and the loading amount is too large.
c. Cell lysis: and adding a proper amount of lysate into each hole, and uniformly spreading the lysate on the bottom of the dish as much as possible. Placing in a refrigerator at 4deg.C or on ice for 5min for cracking.
d. Protein extraction: the cell scraper was rinsed with PBS and the cells were scraped with a scraper on ice. The cell scraper scrapes cells along the same direction as much as possible. Cell extracts in the dish were collected and placed in the EP tube while sucking the liquid on the spatula. When the cell scraper scrapes different groups, the cell scraper should be cleaned and wiped dry.
e. And (3) centrifuging: the protein lysate is cracked on ice for 30min, and the bullet is mixed for 1 time every 5min. 12000g, centrifuging at 4 ℃ for 15min, collecting supernatant, discarding precipitate, and preserving at-80 ℃ until protein is quantified.
(2) BCA method protein content determination
a. Preparation: the extracted protein is placed on an ice bath box to prevent degradation and denaturation.
b. Standard protein preparation: 50mg/mL protein standard was diluted to a concentration of 0.5mg/mL with PBS buffer. 0.5mg/mL protein standard solution 0, 2, 4, 6, 8, 12, 16 and 20. Mu.L were added to 96-well microplates, each set was set in 3 replicates, and the wells were topped up to 20. Mu.L with PBS buffer.
c. Preparing protein liquid to be quantified: the possibility of errors is reduced by adding 76. Mu.L of LPBS buffer to 4. Mu.L of protein test solution, and repeating 3 times every 20. Mu.L, with the remainder. 76 mu L of PBS was added to each EP tube, the proteins were thawed in batches, centrifuged by small vortex, and mixed well. mu.L of the protein solution to be metered was added to 80. Mu.L. mu.L of protein solution was added to each well of the 96-well plate.
d. 200 mu L of working solution is added into each hole, the AB working solution is prepared into solution A, solution B=50:1, and when the working solution is added into a 96-well plate, the gun head is slightly higher than the whole interface so as to avoid cross dyeing.
e. After incubation at 37℃for 30min with a microplate shaker, absorbance was measured at 562nm with an microplate reader.
f. The protein content in the sample was calculated from the standard curve. In Western blot experiments, equal volume and equal amount are adopted for Loading, namely PBS is used for diluting protein samples to consistent concentration, meanwhile, the volume of 5 Xprotein Loading buffer solution (Loading buffer) required by the Loading volume is calculated, and after the concentration is adjusted to be consistent, the volume of 30 mug protein solution is calculated to be the Loading volume.
g. Protein denaturation: after the EP tube sealing film is sealed and marked, the protein is fully denatured in a water bath at 100 ℃ for 10 min. Before sample addition, the sample is centrifugally and evenly mixed for reuse, and the protein is generally stored for 1 month at the temperature of minus 80 ℃ after denaturation and quantification.
(3) SDS-PAGE electrophoresis
a. And (3) glue preparation: selecting corresponding concentration of the separation gel according to the molecular weight of the target protein; cleaning the glass plate, flushing with ultrapure water, and placing the surface contacted with the glue on clean dust-free paper in a downward inclined manner for airing; before the glue is prepared, each solution is placed at room temperature, so that heat generated in the gel process is prevented, and gas dissolved in the storage liquid at low temperature is separated out to generate bubbles. After fixing the rubber plate, the leakage is tested by deionized water, and after testing, the water is wiped clean.
Preparing a separating gel: after the device is determined to be watertight, proper concentration of the separating gel is selected according to the molecular weight of the target protein and gel preparation specification, each component is added according to the required volume, TEMED is added finally, and gel is filled after uniform mixing. After the separating gel is fully and uniformly mixed, the gel is slowly added into the glass at the left side, which is propped against the top end, until the protruding end of the plate is level and slightly higher. After 2/3 of the separating glue is filled, the glue should be sealed immediately, and after the isopropanol is sealed, the glue should be cut and recorded without moving. Generally, a laboratory also often adopts a water seal mode to seal glue, but the flatness of the liquid level is slightly poor. Pouring out the sealing glue solution after gelation, for example, using isopropanol sealing glue to wash the sealing glue with ultrapure water.
Preparing concentrated glue: preparing 5% of concentrated glue according to a glue preparation instruction, filling the concentrated glue along the glass plate, avoiding generating bubbles, enabling the comb to be close to the glass at 45 degrees, quickly inserting the comb into the concentrated glue, slowly inserting the comb when the comb is not solidified, pulling out the comb once the bubbles are generated, and removing the bubbles and reinserting the comb. The gel is solidified for about 1h, and the solidification is favorable for the formation of a gel structure for a long time, because the arrangement of internal molecules is not completed when the gel is observed by naked eyes. Wrapping with ultra-clean paper, adding appropriate amount of ultrapure water for wetting, and sealing and preserving at 4deg.C. Before use, the mixture is put into an electrophoresis liquid to be activated for 10 to 15 minutes and then used. When in use, the glass plate is arranged in an electrophoresis tank, and the electrophoresis buffer solution is added according to the amount. The comb was carefully removed and prepared for loading. Note that observing whether the electrophoresis tank leaks, the leakage can lead to a decrease in conductivity.
b. Loading: after the sample is placed in a refrigerator, proteins can be settled and the solution is heterogeneous. Before loading, melting and centrifuging, and repeatedly mixing or blowing with a gun, and paying attention to replacing the gun head. The gun head or the microsyringe slowly adds the sample into the hole, wherein the 1 st hole needs to be added with 2-5 mu L of Marker. After loading, electrophoresis needs to be carried out as soon as possible, and the electrophoresis conditions are as follows: step1, 80V,30min; step2, 120V,180min, stopping electrophoresis when the Loading buffer goes to the lowest end. Note that: the gun head sucks the protein and inserts into the gel sample hole without extending too much so as to prevent the gun head from stretching the glass plate.
c. Transferring: and cutting PVDF film in advance according to the target protein and the number of samples, and placing the PVDF film in methanol solution for 1-3 min for activation. The glove is dried and the PVDF film is not soaked with water. During the use of the membrane, the membrane is grasped by forceps so as to prevent the PVDF membrane from being polluted by protein on hands. The PVDF film is marked on the upper right when cut to distinguish between the front and back. Soaking a sandwich structure used in the film transferring process in a pre-cooled film transferring liquid at 4 ℃ until the film transferring liquid is completely soaked. The membrane is wetted in advance in the membrane transferring liquid. Washing the gel plate containing the electrophoresis liquid with tap water, and cutting gel of the target protein gel according to the molecular weight of the Marker. The gel was placed flat on the side of the blackboard and the notch in the upper left corner of the PVDF film was aligned with the glue face, according to the principles of a black glue whiteboard. The transfer liquid repeatedly wets the offset plate and the membrane. Until the two are mutually attached without bubbles. And (3) covering the filter paper and silk floss on one side of the membrane, and gently expelling and pressing bubbles by using a test tube until no bubbles are generated between the filter paper and the silk floss. The force is not too great so as to avoid dislocation between the film adhesives. And placing the clamping plate into a membrane electrode groove, and changing black into black and changing red into red. In order to prevent the temperature from being too high during film transfer, an ice bag or the like needs to be placed on one side of the film transfer groove to achieve the purpose of cooling, and the whole film transfer process needs to be carried out in an ice bath. And determining the membrane transfer time and the current required by membrane transfer according to the molecular weight of the target protein.
d. Blocking and hybridization
Closing: at this point, note that the front side of the membrane was distinguished from the back side, the side in contact with the gel was the front side, which was incubated with antibody binding upwards. The membranes were removed, TBST rinsed slightly, immersed in 5% skim milk powder and blocked for 1h. The skimmed milk powder blocks non-specific sites on the PVDF membrane.
Washing the film: the TBST solution is washed for 5-10 min each time, and the total time is 3 times.
Incubating primary antibodies: the primary antibody is diluted in a ratio of generally 1:1000 to 1:10000. The PVDF membrane was then primed with primary antibody facing upward, allowed to pass through the membrane as far as possible, and allowed to stand overnight at 4 ℃. And recovering the primary antibody solution after the incubation is completed.
Washing the film: the TBST solution is washed for 5-10 min each time, and the total time is 3 times. Incubating a secondary antibody: and selecting a proper secondary antibody according to the primary antibody, diluting the secondary antibody according to the proportion of 1:1000, and carrying out light shaking incubation for 1-2 h at room temperature. And after the incubation is finished, recovering the secondary antibody and repeatedly using.
Washing the film: the TBST solution is washed for 5-10 min each time, and the total time is 3 times.
e. Developing: the PVDF film was placed on a developing blackboard, placed horizontally, and the bubbles were removed. Equal volumes of solution A and solution B were mixed, the mixed ECL reagent was gently added dropwise to PVDF membrane and photographed with a gel imaging system. Shooting by a developing instrument, prolonging shooting time and the like. Analysis and scanning are performed. After shooting, the film is recovered and soaked in TBST solution, and can be kept for repeated use. If necessary, the protein bands can be observed with ponceau staining (2% acetic acid, 0.5% ponceau in water) and then rinsed off with deionized water and TBST.
2. Experimental results
2.1H9c2 myocardial cell morphology observations
Cells were divided into 6 groups when observed in morphological experiments: normal control, 1. Mu. Mol/L, 2. Mu. Mol/L, 3. Mu. Mol/L, 4. Mu. Mol/L and 5. Mu. Mol/L DoX treated groups. After DoX stimulation of cardiomyocytes for 24h, cardiomyocytes were observed under an inverted microscope. As a result, as shown in FIG. 23, it was found that the cardiomyocytes of the normal control group H9c2 were spindle-shaped, triangle-shaped or polygonal, were full, and had protrusions of different lengths. Compared with the normal control group, the DoX treatment group with different concentrations has the advantages that the cell bodies of the myocardial cells shrink, the refractive index is reduced, the volume of the cells is obviously reduced, and the cell density is obviously reduced.
2.2MTT detection of H9c2 cardiomyocyte viability
After 2 hours of action of cardiomyocyte treatment in each of the DoX treatment group and the normal control group, MTT cell viability was examined, and the results were shown in FIG. 24, which shows that 1. Mu. Mol/L, 2. Mu. Mol/L, 3. Mu. Mol/L,Compared with the normal control group, the 4 mu mol/L and 5 mu mol/LDoX treatment groups have obvious killing and inhibiting effects on cell viability, and the statistical difference P between the groups is less than 0.01. By calculating half-lethality of H9c2 cell viability, doX concentration was IC 50 =2.46μM。
2.3H9c2 content of NO in cardiomyocyte culture supernatant
The sulfanilic acid in Griess reagent is usually dissolved in an acidic liquid solution, which upon contact with nitrite forms diazonium compounds. Ethylene diamine in the Griess reagent turns the diazo compound into a pink product with maximum absorption at 540nm, and the reaction yields a product concentration that has a linear relationship with the NO concentration. As a result, as shown in FIG. 25, NO significant difference was found in the NO content levels of the 1. Mu. Mol/L, 2. Mu. Mol/L, 3. Mu. Mol/L, 4. Mu. Mol/L and 5. Mu. Mol/LDoX treated groups as compared with the normal control group.
2.4H9c2 content of LDH in cardiomyocyte supernatant
Disruption of cell membrane structure by apoptosis or necrosis results in release of lactate dehydrogenase in the cytoplasm into the medium, under the action of lactate dehydrogenase, NAD + Is oxidized and reduced to NADH, NADH and INT are catalyzed by lipoamide dehydrogenase to generate NAD + And strong color formazan, which produces an absorption peak at 490nm wavelength, whereby lactate dehydrogenase activity can be quantified by occlusion. The results are shown in FIG. 26, where the 3. Mu. Mol/L, 4. Mu. Mol/L and 5. Mu. Mol/LDoX treated groups had a tendency to increase the level of LDH content in the cell culture broth without significant differences, and there was no statistical difference between the groups, as compared with the normal control group.
2.5 Effect of Compounds Hip B and Hip C on H9C2 cardiomyocyte viability
The effect of the compounds Hip B and Hip C on the viability of H9C2 cardiomyocytes was examined by MTT method. As can be seen from FIG. 27, the concentration gradients (0, 0.1, 1, 10, 50 and 100. Mu. Mol/L) of the compounds Hip B, hip C were set to 6 groups, and Hip B had no effect on cell viability at 0 to 100. Mu. Mol/L, whereas Hip C had no toxic effect on H9C2 cardiomyocytes at 0 to 10. Mu. Mol/L, whereas cell viability was significantly decreased at concentrations equal to or greater than 50. Mu. Mol/L. Thus, when the selection compound is used in combination with DoX, the selection of flavonoids is 10. Mu. Mol/L.
2.6 Compounds Hip B and Hip C vs DoX induce LDH levels in H9C2 cardiomyocytes
Lactate Dehydrogenase (LDH) is an important index for detecting apoptosis or necrosis, and as shown in FIG. 28, compound Hip B can significantly reduce LDH level in cells, and compound Hip C can also reduce LDH level in cells to a certain extent. Thus, the compounds Hip B and Hip C have remarkable protective effect on DoX-induced H9C2 myocardial injury.
2.7 Compounds Hip B and Hip C induce NO levels in H9C2 cardiomyocytes against DoX
The level of NO in the cell culture supernatant is an important indicator for detecting whether myocardial cells are damaged or not. As shown in FIG. 29, the compounds Hip B and Hip C can reduce NO level in damaged myocardial cells, and have remarkable protective effect (P < 0.05) on H9C2 myocardial cell damage induced by DoX.
2.8 Effect of Compounds Hip B and Hip C on DoX induced H9C2 myocardial apoptosis proteins
Bcl-2 and Bax regulate apoptosis activators by controlling the permeability of the mitochondrial membrane, and the occurrence of apoptosis is determined by the ratio of Bcl-2 to Bax. As shown in FIG. 30, the neoflavonoid Hyd, hip A, hip B and Hip C all showed protective effect on DoX induced H9C2 myocardial apoptosis.
Test example 3 neuroprotection of Compounds Hip B and Hip C
1. Experimental materials, reagents and instruments
1.1 preparation of the Main reagents
ATRA solution formulation: 15.0mg of all-trans retinoic acid powder is weighed, placed in a sterilized 1.5mL centrifuge tube, added with 1mL of DMSO, vibrated and dissolved to obtain 50mM ATRA solution, subpackaged with 200 mu L centrifuge tube, preserved in a refrigerator at-20 ℃ for standby, and diluted to the required concentration by DMEM culture medium before use.
Preparing an OA solution: each of the okadaic acid contents was 50. Mu.g, which was dissolved in 593. Mu.L of DMSO to give a 100. Mu.M mother liquor, which was packed in 200. Mu.L centrifuge tubes and stored in a refrigerator at-20℃for further use.
Preparing Giemsa solution: (1) preparation of Giemsa stock solution: giemsa powder 0.8g, glycerol 50mL, methanol 50mL. Giemsa powder is dissolved in a small amount of glycerin, fully ground in a mortar, added with methanol, uniformly mixed and shaken, kept at a constant temperature of 56 ℃ for 2 hours, placed in a brown bottle and reserved in a refrigerator at 4 ℃.
(2) And (3) preparing a working solution: and (3) solution A: 11.93g of disodium hydrogen phosphate (Na2HPO4.12H2O) was weighed out by a balance and dissolved in 500mL of ultrapure water; and (2) liquid B: 4.535g of potassium dihydrogen phosphate (KH 2PO 4) was dissolved in 500mL of ultrapure water by a balance; when in use, the solution A is prepared by: and mixing the solution B according to a ratio of 1:1 to obtain the working solution with the pH of 7.0.
(3) Giemsa stock: the working solution=1:4, and the Giemsa staining solution is obtained after uniform mixing and is prepared for use.
Preparing MTT solution: 25.0mg of MTT powder is weighed, 5mL of PBS is added to be fully dissolved, the MTT solution with the concentration of 5mg/mL is obtained, and the MTT solution is packaged and stored in a refrigerator at the temperature of minus 20 ℃ in a dark place.
1.2 Experimental methods
(1) Resuscitating, passaging and culturing cells: before operation, an ultraviolet lamp is turned on to irradiate the ultra-clean workbench for 15min, and alcohol is used for wiping the workbench surface; rapidly placing the cells taken out of the liquid nitrogen tank into a water bath at 37 ℃ for rapid dissolution within 1min, and taking out back and forth to see whether dissolution is performed; transferring the cells in the frozen tube to DMEM medium containing 10% FBS; cell names, times and algebra were marked on petri dishes and incubated in a 5% CO2 incubator at 37 ℃. After the cells are attached, the culture solution is replaced with new culture solution for continuous culture, the cell morphology is observed, and when the cell growth and fusion reach about 80%, the passage operation can be carried out. Discarding old culture solution in the culture dish, and washing for 1 time by PBS phosphate buffer solution; adding trypsin digestion liquid containing 0.25% EDTA, digesting for 30 s-1 min in an incubator, observing under a microscope, adding DMEM culture medium to stop digestion when most cells are almost round and the cell gap is enlarged, and repeatedly and gently blowing off the adherent cells for several times by using a pipetting gun until the cells are completely shed to obtain cell suspension; diluting the uniformly mixed cells according to the required proportion, inoculating the uniformly mixed cells into a new culture medium, and placing the culture medium into an incubator for continuous culture.
(2) Cell cryopreservation: selecting cells in logarithmic growth phase, carrying out passage according to the steps, transferring the collected cells into a sterile centrifuge tube, and centrifuging at the normal temperature of 860rpm for 6min; the supernatant was discarded and DMEM medium was used: FBS: adding the cell cryopreservation solution prepared by DMSO according to a ratio of 5:4:1, lightly blowing and uniformly mixing, and sub-packaging into sterile cell cryopreservation tubes, wherein each tube is 1.2mL; placing in a refrigerator at 4 ℃ for 10min, placing in a refrigerator at-20 ℃ for 1h, and after overnight in a refrigerator at-80 ℃, transferring the cells into a liquid nitrogen tank for preservation.
2. Experimental results
2.1 establishment of an in vitro cell model for AD
As shown in FIG. 31, SH-SY5Y cells in the logarithmic growth phase were taken at 3X 10 4 Each mL was seeded in 6-well plates, and 3mL of cell suspension was added to each well. The culture was continued with DMEM medium containing 10% FBS at 37℃in a 5% CO2 incubator for 24 hours, with the end concentration of ATRA being 5. Mu.M, and with 2% FBS. The morphology was observed every day, the liquid was changed every other day, and the cells were induced for 4 days to become differentiated and mature nerve cells. The original medium was aspirated and the final concentration of OA, 2% FBS in DMEM medium was added for 6h. The cell synapse length was then measured to the cell body length by Giemsa staining and phase contrast microscopy, the ratio calculated using Image probe 6.0, and the model was evaluated for success (Wang YY, song, XY, liu, DD, et al, IMM-H004 reduced okadaic acid-induced neurotoxicity byinhibiting Tau pathology in vitro and in vivo.neuro-toxicity 2019,75:221-232.; medeiros LM, bastani MD, rico, EP, et al, chorinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In Vitro Model for Alzheimer's Disease Studies.mol Neurobiol2019,56:7355-7367.; zhangZ, simple, JW, okadaic Acid Induces Tau Phosphorylation in SH-SY5Y Cells in an Estrogen-presvant able Mantid 2010,1345:176-181.
2.2 Effect of the Compounds Hip B and Hip C on SH-SY5Y cell viability
MTT cell viability principle: succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water insoluble blue-violet formazan and deposit in cells, whereas dead cells do not. The formazan deposited in the cells was dissolved in DMSO, and the number of living cells was determined by measuring its absorbance at 490nm using a microplate reader. The greater OD value indicates greater cellular activity, i.e., less drug toxicity. When the cell viability is higher than 80%, the drug is considered to have no toxic effect on the cells, thereby determining the optimal concentration range for the drug effect. As can be seen from FIG. 32, at treatment concentrations of 0 to 100. Mu.M, the compound Hip B had no effect on cell viability, while the compound Hip C had some effect on cell viability at treatment concentrations of 1 and 50. Mu.M. Therefore, 10 mu M is selected as the optimal concentration of the flavonoid compound in the experiment, and subsequent researches are carried out.
2.3 effects of Hip B and Hip C on morphology of AD cell model
Giemsa's dye solution is a mixture of azurin and eosin, and can dye nuclei into mauve or bluish violet, and cytoplasm into pink, and shows clear cell images under a microscope. The experiment utilizes the method to study the mutation and the transformation of SH-SY5Y cells, and is divided into an ATRA group (normal group), an OA group (damaged group) and a drug treatment group. After 4d induction, ATRA groups continued to be cultured with normal medium containing 2% serum; adding OA culture with final concentration of 40nM into normal culture solution; the drug-treated group was cultured by adding OA at a final concentration of 40nM and Hip B and Hip C at a final concentration of 10. Mu.M to the culture medium at the same time. After 6h Giemsa staining was performed and the change in cell synaptic length was observed, and the experimental results are shown in FIG. 33.
As can be seen from FIG. 33, cells were rounded, shrunken, and the synaptic ratio was significantly shortened after OA treatment. Hip B and Hip C can improve synaptic atrophy caused by OA to some extent, and repair damaged nerve to maintain normal cell morphology.
2.4Western Blotting detection of tau protein phosphorylation-associated protein expression
The brain of an AD patient has obviously raised tau protein phosphorylation level, and has huge prospect for researching and developing medicines for preventing and treating AD aiming at tau protein targets, so the experiment researches the influence of the novel flavonoid compounds on the expression of p-tau Ser 262, p-tau Ser 396 and tau 5 by a Western blotting method. Wherein the ratio of p-tau Ser 262, p-tau Ser 396 to tau 5 represents the degree of phosphorylation of tau protein at serine 262, 396 sites, respectively, the higher the ratio, the higher the degree of phosphorylation. As can be seen from fig. 34, the novel flavonoid compounds of the present invention can significantly reduce the phosphorylation level of tau protein at Ser 262 and Ser 396 sites, indicating the compounds. The novel flavonoid compound has a good effect of improving tau protein hyperphosphorylation, and has potential of treating AD.
In conclusion, the novel flavonoid compounds Hip B and Hip C extracted by the invention can effectively inhibit lipid accumulation in cells, have the effects of repairing myocardial injury, protecting myocardial cells and protecting nerves, and provide more reference bases for developing drugs of potential plant sources for preventing and/or treating related diseases.
The foregoing description is only illustrative of the present invention and is not intended to limit the scope of the invention, and all equivalent structures or equivalent processes or direct or indirect application in other related technical fields are included in the scope of the present invention.
Claims (12)
1. A flavonoid compound is characterized in that the structure is shown as a formula I':
;
wherein R is 1 、R 2 、R 3 、R 4 Are independently selected from H, C1-3 alkyl groups.
2. The compound of claim 1, wherein R 1 、R 2 、R 3 、R 4 Each independently selected from H, methyl.
3. The compound of claim 1, wherein the compound is selected from the group consisting of:
。
4. the use of a compound according to any one of claims 1 to 3, and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the prophylaxis and/or treatment of disorders associated with lipid metabolism.
5. The use according to claim 4, wherein the medicament is a medicament having a lipid lowering effect.
6. The use according to claim 5, wherein the medicament is a medicament for reducing the content of lipid droplets and/or triglycerides in cells.
7. The use according to claim 5, wherein the medicament is a medicament for inhibiting cellular lipid production.
8. The use according to claim 7, wherein the medicament is at least one of FAS inhibitor, SREBP1 inhibitor, SCD-1 inhibitor.
9. The use according to any one of claims 4 to 8, wherein the medicament is at least one of a medicament for preventing and/or treating obesity, hypertension, hyperlipidemia, cardiovascular diseases, metabolic syndrome related diseases.
10. Use of a compound according to any one of claims 1 to 3 for the preparation of at least one of FAS inhibitors, SREBP1 inhibitors, SCD-1 inhibitors.
11. A medicament comprising a compound according to any one of claims 1 to 3.
12. The medicament according to claim 11, characterized in that it comprises compound XVIII, compound XIX, compound IV and/or compound XVII, which has the following structural formula:
、
、
。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010605552.0A CN111704642B (en) | 2020-06-29 | 2020-06-29 | New flavonoid compounds Hip B and Hip C and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010605552.0A CN111704642B (en) | 2020-06-29 | 2020-06-29 | New flavonoid compounds Hip B and Hip C and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111704642A CN111704642A (en) | 2020-09-25 |
CN111704642B true CN111704642B (en) | 2023-12-05 |
Family
ID=72544579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010605552.0A Active CN111704642B (en) | 2020-06-29 | 2020-06-29 | New flavonoid compounds Hip B and Hip C and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111704642B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112353944A (en) * | 2020-11-23 | 2021-02-12 | 湖州师范学院求真学院 | Anticancer combined medicine composition containing compound F-B |
-
2020
- 2020-06-29 CN CN202010605552.0A patent/CN111704642B/en active Active
Non-Patent Citations (2)
Title |
---|
In vitro evaluation of the antioxidant and cytotoxic activities of constituents of the mangrove Lumnitzera racemosa Willd.;Nguyen Phuong Thao,et al.;《Arch. Pharm. Res. 》;第38卷;446-455 * |
沙棘化学成分及药理作用的研究进展;周浩楠,等;《华西药学杂志》;第35卷(第2期);211-217 * |
Also Published As
Publication number | Publication date |
---|---|
CN111704642A (en) | 2020-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111714508B (en) | Application of new flavonoid compounds Hip B and Hip C | |
CN111773232B (en) | Application of new flavonoid compound Hip A | |
CN105481802A (en) | Clerodane diterpenoid compounds, and preparation method and medical application thereof | |
CN111704642B (en) | New flavonoid compounds Hip B and Hip C and application thereof | |
CN111635441B (en) | New flavonoid Hyd and application thereof | |
CN111635445B (en) | New flavonoid compound Hip A and application thereof | |
CN109662962B (en) | Use of oligomeric stilbenes | |
CN111732620B (en) | Extraction method of new flavonoid compounds Hip B and Hip C | |
CN111732621B (en) | Extraction method of new flavonoid compound Hip A | |
CN111732617B (en) | Extraction method of neoflavonoid Hyd | |
CN105943523A (en) | Application of dendrophenol in preparing medicines for inhibiting proliferation of cervical carcinoma cells and for inducing autophagic apoptosis of cervical carcinoma cells | |
CN111840304B (en) | Application of neoflavonoid Hyd | |
CN105503871A (en) | Novel indole alkaloid compound and preparation method and medical application thereof | |
CN104337803A (en) | Application of xerophilusin B in preparation of products for inhibiting tumor growth | |
CN105439989A (en) | Novel diterpenoid compounds as well as preparation method and medicine application thereof | |
CN105481820A (en) | Novel iridoid compound and preparation method and medicinal application thereof | |
CN106146528A (en) | A kind of new diterpene alkaloid compounds and preparation method thereof and medical usage | |
Kraithong et al. | Phytoestrogen constituents and estrogenic activity of Pueraria candollei var. mirifica callus and its extract preparation for removing cytotoxic constituents. | |
CN112358527A (en) | Triptolide acrylate, preparation method and application thereof | |
CN115557922B (en) | Extraction and separation method of peroxy atractylenolide III in codonopsis pilosula and application thereof | |
CN110063949A (en) | Common rabdosia leaf B prime is preparing the purposes in the drug for treating lung cancer | |
CN112402412B (en) | Application of inner ester compound of jingdao in preparing medicine for treating inflammation-caused diseases | |
CN114409557B (en) | Carbon keratin with neuroprotective activity and preparation method and application thereof | |
CN107540687A (en) | A kind of new phloroglucinol derivatives compound and preparation method thereof and medical usage | |
CN110066303B (en) | Method for preparing chrysanthemum new alkyne A from Huai chrysanthemum and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |